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RECOMBINANT HUMAN INTERLEUKIN-7 (CYT107) PROMOTES T CELL
RECOVERY FOLLOWING T-CELL DEPLETED ALLOGENEIC HEMATOPOI-
ETIC STEM CELL TRANSPLANTION
Perales, M.-A.1, Goldberg, J.D.1, Yuan, J.2, Koehne, G.1, Lechner, L.1,
Papadopoulos, E.1, Young, J.W.1, Jakubowski, A.A.1, Zaidi, B.2,
Gallardo, H.2, Liu, C.2, Rasalan, T.2, Wolchok, J.D.3, Croughs, T.4,
Morre, M.4, Heller, G.5, van den Brink, M.R.M.1 1Memorial Sloan-Ket-
tering Cancer Center, New York, NY; 2Memorial Sloan-Kettering Cancer
Center, New York, NY; 3Memorial Sloan-Kettering Cancer Center, New
York, NY; 4Cytheris, Issy LesMoulineaux, France; 5Memorial Sloan-Ket-
tering Cancer Center, New York, NY
Delays in immune recovery after allo-HSCT are associated with
increased risks of infection and relapse. Strategies to enhance T-cell
reconstitution could therefore decrease morbidity and mortality.
Interleukin-7 (IL-7) has a central role in T cell development and
survival. Murine models of allo-HSCT have shown that IL-7 en-
hances thymopoiesis and peripheral T cell survival and expansion.
Initial trials with recombinant human IL-7 (rhIL-7) have demon-
strated a dose-dependent expansion of CD41 and CD81 T cells
in patients with solid tumors or HIV infection. Hence we are
conducting a phase I trial of rhIL-7 (CYT107, Cytheris Inc) in re-
cipients of a TCD allo-HSCT. To date, 10 patients (AML 5 7,
MDS 5 2, CML 5 1; median age 5 57.3, range 27-67) have been
treated with escalating doses of rhIL-7 (3 at 10mcg/kg, 6 at
20mcg/kg, 1 at 30mcg/kg - accrual ongoing) administered SQ
weekly for 3 weeks, starting at a median of 86 (range 60-244)
days post HSCT. Toxicities included grade 2 hypersensitivity
drug rash (n5 3) and grade 2 fever (n5 1). A patient with rash after
the 1st injection (20 mcg/kg level) was removed from the study
(evaluable for toxicity only). No patients have developed GVHD,
anti-IL-7 antibodies or neutralizing antibodies. Two patients
with high-risk AML have relapsed (4 and 9 months post rhIL-7),
an incidence consistent with published data in patients undergoing
allo-HSCT for AML in CR. Nine patients remain alive with a me-
dian follow-up of 14.7 months post rhIL-7. At baseline, the median
T cell counts were 85/mm3 (5-272/mm3), 65/mm3 (9-299/mm3)
and 0 (0-17/mm3) for CD41, CD81 and CD45RA1 T cells, re-
spectively. Immune monitoring after rhIL-7 in 8 evaluable patients
has demonstrated an increase in CD41 T cells (na€ıve or central
memory, 69% median increase at day 21 - range 8%-35-fold in-
crease) and CD81 T cells (na€ıve or effector memory, 94% median
increase at day 28 - range 0-11-fold increase). There was no effect
on CD41CD251FoxP31 T cells or B cells. Increased TCR
excision circles (TRECs) were noted in the 5/6 patients analyzed
indicating enhanced T cell production. Finally, all 3 CMV-sero-
positive patients developed CD81T cell CMV-specific responses,
including a patient with prior CMV viremia and low-level CMV-
specific CD81 T cells prior to rhIL-7 (5.3-fold increase to the
A0201-restricted NLV peptide). Our pre-clinical data and early
clinical results suggest that rhIL-7 enhances immune recovery in
recipients of a TCD allo-HSCT without causing GVHD.218
ADOPTIVE IMMUNOTHERAPY TO PREVENT AND TREAT HHV-6
REACTIVATION POST ALLOGENIC STEM CELL TRANSPLANT
Gerdemann, U.1, Keukens, L.2, Katari, U.L.1, Keirnan, J.M.1,
de Pagter, A.P.2, Heslop, H.E.1, Rooney, C.M.1, Leen, A.M.1 1Baylor Col-
lege of Medicine, Methodist Hospital and Texas Children’s Hospital, Hous-
ton, TX; 2Wilhelmina Children’s Hospital Utrecht, Utrecht, Netherlands
Viral infections cause morbidity and mortality in allogeneic
HSCT recipients. As an effective treatment option, we and others
have successfully infused in vitro expanded cytotoxic T-cell lines
(CTLs) directed against EBV, CMV and Adv. Human herpes virus
type 6B (HHV6B) is detected in . 50% of HSCT recipients and
associated with severe clinical symptoms including pneumonia, en-
cephalitis, acute GvHD, bone marrow suppression and increased
overall mortality. Production of CTLs to this virus has been
hindered by lack of information regarding immunogenic/protective
target antigens.
To identify immunodominant T cell targets in HHV6, we as-
sessed the cellular immune response directed against 5 HHV6Bantigens (U71, U90, U11, U14 and U54), whose counterparts in
the significantly homologous CMV or HHV7 viruses were found
to be immunogenic. For T cell stimulation we isolated PBMCs
from HHV6 sero1ve, CMV sero-ve donors (thus eliminating
the possibility of cross-reactive T cell recognition), pulsed them
with peptide libraries spanning each antigen, and then expanded
them in vitro in the presence IL-4 and IL-7 for 10 days. The re-
sulting CTLs were predominantly CD41 (mean 62%1/-6%)
with specificity for all stimulating antigens. Using IFNg ELIspot
we were able to identify a hierarchy of immunodominance. In 3
donors, we found that all donors responded to all 5 antigens,
but the magnitude of the response differed. The frequency of T
cells reactive against U90 was 216 median SFC/2x105, range
114-804, followed by U11 (median 196, range 70-202), U14 (me-
dian 165, range 134-237), U54 (median 126, range 51-248) and
U71 (median 47 SFC, range 12-50). To confirm that our chosen
antigens are relevant targets for future immunotherapy studies we
next assessed whether the same profile of specificity was generated
using PBMC as stimulator cells that were infected with the
HHV6B Z29 wild type virus, which has a natural tropism for an-
tigen presenting monocytes and CD4 T cells. On day 10 the ex-
panded T cells were specific for U90 (5/5 donors), U54 (4/5) and
U14, U11 (3/5) and U71 (1/5), with a similar frequency of reactive
cells as using peptide stimulation.
In summary we were able to generate and characterize T cell im-
munity to 5HHV-6B antigens in healthy seropositive donors. These
antigens can now be used to further characterize endogenous T cell
recovery in patients after allogenic stem cell transplantation and to
generate HHV-6B specific CTL for adoptive transfer.219
THE EFFECT OF DONOR CMV SEROSTATUS ON CMV INFECTION AND
OUTCOME IN ALLOGENEIC STEM CELL TRANSPLANT RECIPIENTS
Green, J.S.1,Mulroney, C.M.2, Curtin, P.T.2, Taplitz, R.A.1 1University
of California San Diego, San Diego, CA; 2University of California San
Diego, San Diego, CA
Background: Cytomegalovirus (CMV) is an immunmodulatory
herpes virus that significantly contributes to morbidity of allogeneic
stem cell transplant (SCT) recipients. Risk factors for early CMV re-
activation include recipient serostatus, use of total body irradiation,
older age, graft versus host disease (GVHD) and matched unrelated
donor (MUD) transplants. The impact of CMV seropositve donor
status on the incidence and outcome of CMV infection in a seropos-
itive recipient is widely debated. In this study we have identified risk
factors for CMV infection in our patient population and evaluated
the impact of donor serostatus on the incidence and outcome of
CMV infection.
Methods:One hundred and eighty-five consecutive allogeneic SCT
recipients at Moore’s Cancer Center, University of California San
Diego from January 2005-August 2009 were identified and charts
retrospectively reviewed.
Results: Sixty percent (112/185) of SCT’s were related with 40%
(73/185) being matched unrelated donor (MUD). An equal amount
of related and MUD were myeloablative (60%) and non-myelobla-
tive (40%) respectively. The incidence of CMV infection (reactiva-
tion) was 39.5% (73 patients) with 82% (60 patients) reactivating
early (before day 100) at a median day 134 post transplant.
CMV disease developed in 8.1%. CMV seropositve recipients
and Asian Pacific race were significantly associated with CMV in-
fection in multivariate analysis with an OR of 9.15 (95% CI 3.55,
23.63) and 6.20 (95% CI 1.24, 31.03) respectively. CMV seroneg-
ative donor/ seropositive recipient (D-/R1) status was significantly
associated with multiple reactivations ($ 3, p\ .0041), high grade
CMV viremia (p.0286) and increased length of CMV viremia
(p.0038) as compared to CMV seropositive donor/seropositive re-
cipients (D1/R1). Neither CMV reactivation nor donor/recipient
serostatus statistically affected survival at 100 or 365 days post
transplant.
Conclusion: Patients with CMV D1/R1 transplants that went on
to develop CMV infection had improved virus control compared
to CMV (D-/R1) SCT as measured by multiple reactivations,
peak viremia and length of viremia. Donor CMV serostatus should
Poster Session I S235be a consideration in the pre-transplant evaluation. Studies are
needed to further delineate the immunologic impact of donor
serostatus.220
CMV SPECIFIC T CELLS PREVENT PROGRESSION FROM LOW TO HIGH
LEVEL VIREMIA IN D1R1 BUT NOT D-R1 PATIENTS
Hoegh-Petersen, M.1, Roa, L.1, Liu, Y.1, Zhou, F.1, Ugarte-Torres, A.1,
Louie, P.1, Fonseca, K.2, Khan, F.1, Storek, J.1 1University of Calgary,
Calgary, AB, Canada; 2Alberta Health Services, Calgary, AB, Canada
Background:Cytomegalovirus (CMV) reactivates (becomes detect-
able in blood) in most seropositive hematopoietic cell transplant
(HCT) recipients. In some reactivating patients, low level viremia
(\ 50,000 DNA copies/ml plasma, ie, less than our institutional
threshold for preemtive therapy) progresses to high level viremia
or CMV disease, which is potentially fatal. We hypothesized that
low level viremia progresses in patients with low specific T cell
counts and spontaneously resolves in patients with high specific T
cell counts.
Methods: In 30 CMV seropositive HCT recipients monitored
weekly for reactivation by real-time PCR, blood was drawn for
specific T cell counts within 4 days from the first episode of
low level viremia. Fourteen patients received grafts from seropos-
itive donors (D1R1), and 16 patients from seronegative donors
(D-R1). Mononuclear cells were stimulated overnight with
CMV lysate, pp65 overlapping peptides, no stimulus (negative
control) or staphylococcal enterotoxin B (positive control). T cells
producing IFNg, TNFa and/or IL2 were enumerated by flow cy-
tometry.
Results: Among D1R1 patients, counts of CMV lysate and pp65
specific CD4 T cells producing IFNg and TNFa (and not IL2)
were higher in patients with spontaneous resolution than patients
with progression (p 5 0.02 for CMV lysate, p 5 0.004 for pp65).
Also, there was an inverse correlation between pp65 specific CD8
T cells producing IFNg and TNFa and peak viremia (r 5 -0.94, p
5 0.005) in D1R1 patients who progressed to high level viremia/
disease. In contrast, among D-R1 patients, CMV lysate and pp65
specific T cell counts were similar in patients with spontaneous res-
olution and patients with progression, and there was no correlation
between specific T cell counts and peak viremia.
Conclusion:CMV specific T cells play a role in preventing progres-
sion from low to high level CMV reactivation/disease in D1R1
patients. Other immune mechanisms (eg, NK cells?) play the role
in D-R1 patients.221
ASSESSMENT OF IMMATURE RETICULOCYTE FRACTION AS AN EARLY
PREDICTOR OF MARROW ENGRAFTMENT AFTER HEMATOPOIECTIC
STEM CELL TRANSPLANTATION
Kim, N.H.1, Chun, B.C.2, Kim, H.1, Lee, J.W.1, Hong, K.T.1,
Kim, M.S.1, Kang, H.J.1, Park, K.D.1, Shin, H.Y.1, Ahn, H.S.1 1Seoul
National University College of Medicine, Seoul, Korea; 2Korea University,
Seoul, Korea
Introduction: Hematopoietic stem cell transplantation (HSCT)
has been used as a treatment for hematologic malignancies and
non-malignant disorders. The success of engraftment is important
for determining the direction of treatment and the prognosis
of patients. Various methods of early assessment have been
proposed. The purpose of this study was to evaluate immature
reticulocyte fraction (IRF) as an early predictor of marrow
engraftment and to validate cut-off values for IRF in pediatric
patients.
Patients and Methods: Retrospective analysis was performed on
172 patients including 108 males (62.8%) and 64 females
(37.2%) with a median age of 8.3 years who underwent HSCT
(autologous: 87 patients, allogeneic: 85 patients) in Seoul Na-
tional University Children’s hospital from January 1st, 2005 toDecember 31st, 2008. Complete blood counts with reticulocyte
parameters were measured in all patients. The day of engraftment
of neutrophil was defined as the first of three consecutive days of
an absolute neutrophil count . 500 /mL with GCSF support. En-
graftment of platelets was defined as an unsupported platelet
count over 20,000/mL for seven days.
Results: Standard neutrophil engraftment occurred after a mean of
12.164.3 days following HSCT and platelet engraftment occurred
after a mean of 19.4611.7 days. With regards to IRF, mean rates
were as follows: above 1% after 9.662.6 days, above 3.5% after
10.563.0 days, and above 5% after 11.163.6 days. These differences
was statistically significanct for IRF and platelets when compared
with standard neutrophil recovery after HSCT. Following HSCT,
themean day on which IRF increased above 3.5% preceded the stan-
dard neutrophil engraftment day (P\0.001). The predicting cut-off
value of IRF was 3.5% (AUC 5 0.879, 95% CI, 0.759-0.999) at 8
days after HSCT. Sensitivity and specificity were 86.7% and
82.8%, respectively.
Conclusions: Considering these results of the increase in IRF
preceded that of absolute neutrophil count (ANC) or platelets
in most cases, IRF was useful as an early indicator of marrow en-
graftment especially when observed simultaneously with the other
parameters.222
EXTRATHYMIC SITES DRIVE THYMUS-INDEPENDENT DEVELOPMENT OF
FUNCTIONAL T CELLS AFTER BONE MARROW TRANSPLANTATION
Holland, A.M.1,2, Zakrzewski, J.L.1, Fletcher, A.L.3, Smith, O.M.1,
Suh, D.1, King, C.G.1, Yim, N.L.1, Rao, U.K.1, Brill, J.1, van den
Brink, M.R.1 1Memorial Sloan-Kettering Cancer Center; 2Weill Cornell
Graduate School of Medical Sciences; 3Dana Farber Cancer Institute
T cell deficiency after bone marrow transplantation (BMT) leads
to significant morbidity andmortality due to infection andmalignant
relapse. We have previously shown that CD4-CD8- T cell precur-
sors (preT) generated via OP9-DL1 coculture improve thymic and
peripheral T cell reconstitution when administered at the time of
BMT. While the thymus supports T cell development into old
age, adult BMT recipients have limited thymic function due to
age-related involution and additional injury caused by transplant
conditioning. We therefore hypothesized that T cell reconstitution
after BMT may depend to some extent on extrathymic T cell
development, which has previously been described as present but
abnormal.
We found that, in addition to the thymus, preT cells engrafted in
extrathymic sites, including mesenteric lymph nodes (MLN), pe-
ripheral lymph nodes (PLN) and spleen, within 24 hours of transfer
into euthymic BMT recipients. We detected CD41CD81 (double
positive, DP) thymocyte-like cells of both preT and bone marrow
(BM) origin in MLN, but not PLN, BM, or spleen, suggesting T
cell development in MLN. Using a novel dual reporter for biolumi-
nescence imaging we confirmed that preT trafficked to gut-associ-
ated tissues, where they underwent NFAT activation, consistent
with T cell development. In competitive reconstitution studies we
found that engraftment of preT in thymic and extrathymic sites re-
quired PSGL-1, while CCR9 may be dispensable.
To better study extrathymic T cell development, we transferred
preT into thymectomized or athymic BMT recipients. We demon-
strated that preT and BM cells develop into both TCRab and
TCRgd T cells in athymic BMT recipients. As in euthymic recipi-
ents, preT engraft in extrathymic gut-associated sites andMLN sup-
port DP early after transfer into athymic BMT recipients.We found
more CD41, CD8ab1, and CD8aa1 T cells in the spleen, PLN,
MLN, and Peyer’s patches of athymic BMT recipients that received
preT than in nontransplanted or BM only recipients. Extrathymic-
derived CD41 and CD8ab1T cells are naive CD44- cells with a di-
verse T cell receptor (TCR) repertoire. In addition, extrathymic-de-
rivedT cells proliferated to a similar extent as thymic-derived T cells
and produced IFNg and TNFa following in vitro stimulation. In
conclusion, using adoptively transferred preT, we have
